ALKS
Alkermes Plc
NASDAQ · Healthcare · Biotechnology · IE
$45.15
−1.19%Next report
Analyst consensus
- Next report date
- Feb 24, 2027
- EPS estimate
- -$0.13
- Revenue estimate
- $464.0M
Latest reported
- Last report date
- Nov 3, 2026
- EPS actual
- $0.09
- EPS estimate
- -$0.08
- Revenue actual
- $480.1M
- Revenue estimate
- $463.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +714.6%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $60
- PT range
- $56 – $62
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 3, 2026 | -$0.08 | $0.09 | Beat 210.09% | $480.1M |
| Jul 28, 2026 | -$0.03 | $0.70 | Beat 2650.09% | $496.0M |
| May 5, 2026 | -$0.57 | -$0.40 | Beat 29.82% | $392.9M |
| Feb 25, 2026 | $0.43 | $0.29 | Miss -32.00% | $384.5M |
| Jul 29, 2025 | $0.42 | $0.52 | Beat 24.11% | $390.7M |
| May 1, 2025 | $0.25 | $0.13 | Miss -48.92% | $306.5M |
| Feb 12, 2025 | $0.81 | $1.04 | Beat 28.40% | $430.0M |
| Oct 24, 2024 | $0.74 | $0.72 | Miss -2.70% | $378.1M |
| Jul 24, 2024 | $0.70 | $0.70 | In line | $399.1M |
| May 1, 2024 | $0.59 | $0.44 | Miss -25.42% | $350.4M |
| Feb 15, 2024 | $0.46 | $0.48 | Beat 4.35% | $377.5M |
| Oct 25, 2023 | $0.44 | $0.64 | Beat 45.45% | $380.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 24, 2027